Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Value of EGFR Expression, KRAS Mutation and Tumor Sideness in Patients With Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI as a Third- or Fourth-line Setting

NCT03698253 is registered in ClinicalTrials.gov with Kaohsiung Medical University Chung-Ho Memorial Hospital as lead sponsor.

NCT NCT03698253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03698253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Value of EGFR Expression, KRAS Mutation and Tumor Sideness in Patients With Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI as a Third- or Fourth-line Setting
Lead sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase
Not applicable
Overall status
Completed
Start date
October 1, 2013
Completion date
June 1, 2018
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer